Login to Your Account

Nektar, BMS pair graduates with honors across several tumor types

By Randy Osborne
Staff Writer

Monday, November 13, 2017

Nektar Therapeutics Inc.'s vice president of clinical development, Mary Tagliaferri, told BioWorld that the compelling objective response rate and impressive DCR with NKTR-214 when paired with Opdivo likely put the program in line for accelerated approval.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription